Location History:
- Woodbridge, CT (US) (2005 - 2010)
- S. Glastonbury, CT (US) (2013)
- South Glastonbury, CT (US) (2011 - 2017)
Company Filing History:
Years Active: 2005-2017
Title: Innovations by Andreas Windemuth in Pharmacogenomics
Introduction
Andreas Windemuth, an accomplished inventor based in South Glastonbury, Connecticut, has made significant contributions to the field of pharmacogenomics. With a total of seven patents to his name, his innovations primarily focus on methods that enhance drug metabolism predictions, tailoring treatments to individual genetic profiles.
Latest Patents
Among his notable patents is the "Physiogenomic method for predicting drug metabolism reserve for antidepressants and stimulants." This patent discloses compositions and methods relevant to a novel Drug Metabolism Reserve Physiotype, which determines the metabolic capacity of individuals based on a blood sample. In the innovative process, individuals are genotyped for various polymorphisms in genes such as CYP2C9, CYP2C19, and CYP2D6, enabling the production of four new indices that relate to the person's metabolic capacity.
Another significant patent is the "Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones." This patent identifies genetic markers associated with the safety and efficacy of thiazolidinedione therapy. It utilizes a physiogenomic methodology that correlates these markers with physiological responses, focusing on important side effects like BMI increase and the development of edema while also linking efficacy markers with glycosylated hemoglobin.
Career Highlights
Throughout his career, Andreas Windemuth has worked with notable companies, including Genomas, Inc. and Genaissance Pharmaceuticals, Inc. His innovative approaches to drug metabolism and therapy safety reflect his commitment to advancing personalized medicine.
Collaborations
Andreas has collaborated with esteemed professionals such as Gualberto Ruano and John W. Goethe. These collaborations have likely enriched his research endeavors, fostering an environment of shared knowledge and expertise.
Conclusion
Andreas Windemuth continues to be a prominent figure in the field of pharmacogenomics, driving innovations that have the potential to improve patient outcomes through personalized medicinal approaches. His groundbreaking patents not only reflect his ingenuity but also pave the way for future advancements in tailored therapeutic practices.